Cite
Malvehy J, Samoylenko I, Schadendorf D, et al. Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB-IVM1c melanoma. J Immunother Cancer. 2021;9(3)doi: 10.1136/jitc-2020-001621.
Malvehy, J., Samoylenko, I., Schadendorf, D., Gutzmer, R., Grob, J. J., Sacco, J. J., Gorski, K. S., Anderson, A., Pickett, C. A., Liu, K., & Gogas, H. (2021). Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB-IVM1c melanoma. Journal for immunotherapy of cancer, 9(3), . https://doi.org/10.1136/jitc-2020-001621
Malvehy, Josep, et al. "Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB-IVM1c melanoma." Journal for immunotherapy of cancer vol. 9,3 (2021). doi: https://doi.org/10.1136/jitc-2020-001621
Malvehy J, Samoylenko I, Schadendorf D, Gutzmer R, Grob JJ, Sacco JJ, Gorski KS, Anderson A, Pickett CA, Liu K, Gogas H. Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB-IVM1c melanoma. J Immunother Cancer. 2021 Mar;9(3). doi: 10.1136/jitc-2020-001621. PMID: 33785610; PMCID: PMC8011715.
Copy
Download .nbib